

QUARTERLY ACTIVITIES & CASHFLOW REPORT

PERIOD ENDING 30 JUNE 2026

BRISBANE, AUSTRALIA, 20 July 2026: AnteoTech Ltd (ASX: ADO) (**AnteoTech** or the **Company**), a supplier of chemicals and advanced material solutions to the Lithium-ion Battery (LiB) and Life Sciences diagnostic markets, is pleased to provide its Activities Update and Appendix 4C Quarterly Cash Flow Report for the period ended 30 June 2026 (the “**Quarter**”). All financial results are in Australian dollars and unaudited.

The June 2026 quarter saw significant commercial and technical progress across both the Advanced Battery Technologies (ABT) and Life Sciences (LS) businesses, together with a material strengthening of the Company’s balance sheet. During the quarter, the Company achieved independent commercial-format cell-level validation of its Ultranode™ 95 high silicon anode in relation to its suitability for use in military drone batteries, launched a new ABT product, secured new international distribution and collaboration partners across Japan and South Korea and completed the initial stage of its collaborative CLIA product development program with a large global life sciences company.

The full exercise of the Company’s listed ADOO options, supported by an underwriting agreement, raised approximately A\$10.0 million (before costs), materially strengthening the Company’s cash position. These funds will be used to accelerate commercialisation activities across both businesses.

HIGHLIGHTS

Advanced Battery Technologies

- **Independent third-party validation of Ultranode™ 95 was completed by the Battery Innovation Centre (BIC) in Indiana, USA, using a 5 Ah Multi-Layer Pouch (MLP) commercial cell format, a format used in drone and UAV battery packs. Ultranode™ 95 is able to achieve more than 390 Wh/kg at the cell level (approximately 40% higher energy density than conventional graphite-based cells) and completed more than 300 charge–discharge cycles at 70% capacity retention, exceeding the 200-cycle standard cited for defence drone battery performance.**¹



Figure 1: MLPs with Ultranode™ 95 anodes assembled for testing at BIC

¹ ASX Announcement 21 May 2026

- BIC reported the program as one of the most straightforward scale-ups it had observed, providing strong confidence in the manufacturability and scalability of the Ultranode™ technology. Roll-to-Roll samples of Ultranode™ 95 produced at BIC have been dispatched to US-based drone battery manufacturers and other parties. Early-stage trial discussions with Australian defence-sector drone suppliers have also commenced. This would likely involve cylindrical format cells, which are now being manufactured and trialled at BIC.
- A Strategic Collaboration and Sales Agreement Term Sheet was signed with South Korea's Xerabrid Corporation to combine Anteo S™ with Xerabrid's high performance separator design, testing and manufacturing capability, accelerating customer testing, product optimisation and the commercial adoption of next-generation separators.² This collaboration has now progressed, with joint meetings underway with agreed initial target customers.
- Anteo C, a new ABT product which was launched during the Quarter, is a water-based, PFAS-free cross-linker additive to primer coatings used on copper (anode) and aluminium (cathode) current collectors. It enables the use of water-soluble binders improving adhesion, decreasing contact resistance and protecting against corrosion. Following successful laboratory and pilot-scale trials with a South Korean customer, a 20L manufacturing-scale sample was shipped for evaluation on aluminium current collectors for water-based Lithium Iron Phosphate (LFP) cathode production.³
- With the launch of SiMRAX, Anteo S™ and Anteo C, the Company has introduced three new ABT products during FY2026, broadening its addressable market across the LiB value chain beyond the high silicon anode product Anteo X® and Ultranode.™ Figure 2 shows where each product delivers value in an LiB.




Figure 2: Electrochemical unit schematic for a LiB excluding electrolyte

- Negotiations continued on two non-exclusive Ultranode™ 95 Joint Development Agreements with US battery manufacturers supplying, or intending to supply, drones into the US defence or military sector and broader drone market.

² ASX Announcement 26 May 2026

³ ASX Announcement 30 June 2026

Life Sciences

- The Company appointed Tokyo Stock Exchange-listed Cosmo Bio Co., Ltd (TSE: 3386) as a non-exclusive distributor of AnteoBind™ and related products in Japan, effective immediately. Cosmo Bio has a well-established domestic distribution model, servicing life sciences companies as well as universities and public research institutes throughout Japan.⁴
- The initial stage of the collaborative chemiluminescent immunoassay (CLIA) product development program with a large global life sciences company was completed, further validating AnteoBind™ NXT activated magnetic particles for use on large-scale automated CLIA diagnostic platforms. The Company recognised A\$61,595 in related revenue in FY2026⁵, and has progressed to the next stage of work with the company.
- The CLIA White Paper, published in late March 2026, together with the successful CLIA product development program completed with the large global life sciences company, supports the launch of a new AnteoBind™ NXT CLIA Kit at the ADLM Conference in the USA this month. Figure 3 shows this Kit.



Figure 3: Representation of CLIA Kit to be launched at ADLM

- The Company continued to receive recurring Life Sciences revenue under its five-year take-or-pay supply agreement with the Serum Institute of India (SII). The Company shipped \$134,138 of AnteoBind™ product to SII in early July 2026. As the shipment was delivered post 30 June 2026, this will be recorded as FY2027 income.
- The use case for AnteoBind™ continues to expand, particularly with researchers in India, across a range of platforms. These use cases will be detailed over the coming quarter through use case studies and media.

⁴ ASX Announcement 28 May 2026

⁵ ASX Announcement 1 July 2026 post period end

Corporate

- The Company entered an underwriting agreement with MST Financial Services Pty Ltd⁶ in respect of its listed ADOO options (exercise price A\$0.035, expiring 31 May 2026). All options were exercised, with 286,628,688 new fully paid ordinary shares issued (118,326,435 quoted on 2 June 2026 and 168,302,253 quoted on 5 June 2026), raising ~A\$10.0 million before costs.
- Subsequent to quarter end, in July 2026, Mr Fabian Beck, Vice President of International Sales, departed the business. Global sales activities are now organised and coordinated centrally from the Company's Brisbane head office.
- The Company's ARENA grant milestone timeline was extended to 15 November 2026.
- Mr Scott Waddell was confirmed as permanent Chief Financial Officer and Company Secretary on 17 July 2026.
- The Company closed the quarter with a materially strengthened cash position of A\$11.2 million and no bank debt (other than lease & asset-finance liabilities as at 30 June 2026).

AnteoTech Managing Director & Chief Executive Officer Merrill Gray commented: *"The June 2026 quarter has seen significant progress by AnteoTech, both commercially and financially. Independent validation of Ultranode™ 95 in relation to its suitability for use in drones, in a commercial scale cell format, the launch of Anteo C, growing demand for Anteo S™ samples and our new collaboration and distribution partnerships in high performance separators in Japan and South Korea respectively, demonstrate the breadth and reflect the momentum building across the business.*

"With three new ABT performance additive products released in FY2026 and pathways into the large global CLIA market identified, we are significantly expanding the markets our products can service and are receiving strong sample demand as a result.

"We have centralised and grown our sales and marketing team and continue to build our marketing capabilities in order to continue to increase brand awareness. Significantly more multi-channel media coverage of the Company was achieved during the quarter. The strong support we received for our option exercise has provided the balance sheet strength to convert this technical and commercial progress into sales as we move into FY2027."

⁶ ASX Announcement 29 May 2026

A. ADVANCED BATTERY TECHNOLOGIES (ABT)

1. ULTRANODE™ 95 – INDEPENDENT VALIDATION IN COMMERCIAL 5Ah MLP CELLS BY THE BATTERY INNOVATION CENTRE (BIC), USA

During the quarter, independent third-party validation of Ultranode™ 95 was completed by the Battery Innovation Centre (BIC) in Indiana, USA, in a 5 Ah Multi-Layer Pouch (MLP) commercial cell configuration. This format is commonly used in drone and UAV battery packs as are cylindrical cells. This validation built on the coin cell and Single Layer Pouch cell validation reported in the prior quarter and represents an important step towards commercialisation.

The results confirmed that Ultranode™ 95 is able to achieve more than 390 Wh/kg at the cell level, approximately 40% higher energy density than cells built on conventional graphite anodes and completed more than 300 charge and discharge cycles at 70% capacity retention, exceeding the 100 to 200 cycle standards cited for defence drone battery performance, as shown in Figure 4 below.




Figure 4: Example cycle life graph of Ultranode™ 95 in a 5 Ah MLP cell tested at BIC at a charge/discharge rate of 1C/1C

In its independent assessment, BIC described the program as one of the most straightforward scale-up efforts it had observed, providing strong confidence in the manufacturability and scalability of the technology. Ultranode™ 95 uses low-cost micro-silicon sourced from established suppliers across the US, South Korea and Europe, supporting supply-chain diversification and reliability alongside its performance advantage.

Roll-to-Roll production samples produced at BIC were subsequently quality assessed and dispatched to a number of US-based drone battery manufacturers with which the Company is in discussion. Discussions are also progressing with Australian defence sector drone suppliers around trials.

2. ULTRANODE™ 95 DRONE MARKET, JDA NEGOTIATIONS CONTINUING

Two non-exclusive Ultranode™ 95 Joint Development Agreements (JDAs) remain under negotiation with battery manufacturers that supply, or intend to supply, drones into the US defence or military sector

and the broader drone market. The BIC commercial-format validation strengthens the Company's position in these discussions.

3. ANTEO S™ – STRATEGIC COLLABORATION AND SALES AGREEMENT TERM SHEET WITH XERABRID (SOUTH KOREA)

On 26 May 2026, the Company signed a Strategic Collaboration and Sales Agreement Term Sheet with Xerabrid Corporation, a South Korean separator technology company with R&D facilities and pilot-scale manufacturing capability. The collaboration seeks to combine AnteoTech's separator cross-linking technology, Anteo S™, with Xerabrid's high-performance separator design, testing and manufacturing expertise to accelerate customer testing, product optimisation and commercial adoption across next-generation separator applications in South Korea and other markets.

The engagement followed Xerabrid's evaluation of Anteo S™ in ceramic coated separator applications prior to the Company's March 2026 visit to South Korea and is expected to accelerate access to the highly advanced Korean separator manufacturing ecosystem. It complements the Company's existing Korean distribution relationship with Kangshin.

Anteo S™ can be applied across a wide range of battery chemistries, including high silicon, graphite, silicon composite, lithium sulphur, lithium metal and sodium-ion. A significant number of requests from separator manufacturers globally were received during the quarter, with Anteo S™ currently being tested at pilot scale by customers in Asia and the United States.

4. ANTEO C – NEW PRODUCT LAUNCHED AND SHIPPED FOR SCALE TRIALS

On 30 June 2026, the Company launched Anteo C, a new performance enhancing cross-linker additive for use in primer coatings applied to copper foil (anode) and aluminium foil (cathode) current collectors in LiBs. Anteo C is water-based and PFAS-free and integrates into existing aqueous primer coating processes.

The primer coating industry is increasingly moving toward lower-cost, water-based binders, which offer cost and environmental advantages but can dissolve when water-based active material slurries are applied during electrode manufacturing. Anteo C cross-links the molecular structure of these binders, stabilising the primer coating, reducing the risk of dissolution and improving the mechanical and electrochemical properties of the electrode allowing manufacturers to effectively use lower-cost, water-soluble binders.

Anteo C progressed rapidly through evaluation with a South Korean primer coating customer. After an initial 100 mL laboratory-scale sample, a 5 L sample was requested for pilot-scale Roll-to-Roll coating trials, which were completed successfully and the coated material was then provided to an end customer for evaluation. The contract coater then requested a larger, 20 L, sample which the Company then shipped for manufacturing-scale evaluation of primer coatings on aluminium current collectors for water-based lithium iron phosphate (LFP) cathode production.

The Company's South Korean distributor, Kangshin, is working to identify and engage additional Anteo C customers in the region. The ABT team has also expanded outreach to a large potential customer in India and received a positive response.

5. ABT PRODUCT PORTFOLIO EXPANSION

With the launch of SiMRAX, Anteo S™ and Anteo C, AnteoTech's ABT product portfolio has expanded its LiB addressable market beyond Anteo X® and Ultranode™ for high silicon anodes. This creates additional commercial pathways for the Company to capitalise on.

All products are available at sample, pilot and commercial scale from AnteoTech's ISO 9001 certified 20,000 L manufacturing facility in Brisbane, which has approximately 1 GWh per year expandable production capacity and laboratory facilities.

6. SiMRAX

SiMRAX, the joint product developed with US-based Black Diamond Structures (BDS) under the Joint Development and Sales Agreement (JDSA) announced in September 2025, combines AnteoTech's Anteo X® with BDS's proprietary Molecular Rebar® single-walled carbon nanotube (SWCNT) dispersion technology. This product is currently under evaluation by six companies, with further companies under negotiation and targeted to receive samples, as outlined in Table 1 below.

SiMRAX is an all-in-one binder-strengthening system that has demonstrated in-house and third-party testing capacity to deliver more than 50% higher cycle life in high silicon anode cells at ultra-low CNT loadings, supporting meaningful cost reductions while also improving slurry rheology. Following the dispatch of first trial sample run samples in the March 2026 quarter, customer evaluations continued through the June quarter, targeting battery manufacturers using greater than 15wt.% silicon anode formulations. SiMRAX samples have also been, or will be, provided to cathode manufactures (specific chemistry) and to customers outside the US, including three European and one Australian company.

No.	Company	1 st Sample	Lab-scale testing	Prototyping	2 nd Sample	Scale-up
1.	Defence battery manufacturer	Received	Complete - Positive	In progress		
2.	Defence battery manufacturer	Received	Complete - Positive	N/A		
3.	Advanced cathode technology manufacturer	Received	In progress			
4.	Advanced anode technology manufacturer	Received	In progress			
5.	Advanced cathode technology manufacturer	Received	In progress			
6.	Advanced anode technology manufacturer	Received	In progress			
7.	Large-scale battery manufacturer	Under negotiation				
8.	Medium-scale battery manufacturer	Under negotiation				

Table 1: Current customer evaluations pipeline for SiMRAX product

N/A - Company restructure and move away from battery design and manufacture has stopped work.

AnteoTech's partner BDS manages sample logistics and supports customer identification and qualification. Both companies continue to work together to qualify and expand the SiMRAX customer

base. During the September 2026 quarter, feedback on results, including next steps and additional sample despatches is expected. Conversion to sales will be subject to positive customer evaluation feedback and any further product refinement.

7. ULTRANODE™ 70 – WYON AG COMMERCIAL CELL DEVELOPMENT CONTINUING

Ultranode™ 70 continued to be evaluated by Wyon AG (Wyon), a Swiss manufacturer specialising in rechargeable miniature and micro batteries (in the 20 µAh to 400 mAh range) and a market leader in batteries for medical technologies such as hearing devices. Following the validation of Ultranode™ 70 against the AnteoTech baseline in coin cell testing last quarter, Wyon continued the development and assembly of its proprietary miniature commercial form-factor cells and commercial charge and discharge (cycle) testing during the quarter, as shown in Figure 5 below.




Figure 5: Four Wyon Ultranode™ 70 miniature commercial form-factor cell assemblies prior to testing.

Testing by Wyon is an important step in validating Ultranode™ 70 under real-world commercial cell design and manufacturing conditions. Testing is conducted independently by Wyon, with AnteoTech supporting the program through a dedicated team and regular update meetings on the structured testing program. Integration of Ultranode™ 70 into Wyon's cells is targeting delivery of up to approximately 30% greater energy capacity compared with Wyon's current graphite-based commercial form-factor batteries.

As previously advised, the timeline for completion of Wyon's commercial form-factor cell evaluations has been extended. On successful completion and achievement of the targeted performance improvement milestones, AnteoTech and Wyon intend to seek to negotiate a commercial supply arrangement for Ultranode™ 70. In the interim, the AnteoTech sales team continues to seek end-use applications and customers to support these negotiations.

B. LIFE SCIENCES

1. CLIA PRODUCT DEVELOPMENT PROGRAM – INITIAL WORK PROGRAM COMPLETED

Subsequent to quarter end, on 1 July 2026, the Company announced completion of the initial stage of its collaborative CLIA product development program with a large global life sciences company. The program validated AnteoBind™ NXT activated magnetic particles for use on large-scale automated CLIA diagnostic platforms.

The Company recognised A\$61,595 in related revenue in FY2026 for this work. The successful outcome has led to the next phase of work with the partner and validates a key technical step towards CLIA market entry, particularly when combined with the activation results achieved with other magnetic particles set out in the Company's "CLIA White Paper" published in late March 2026 (available on request). These results demonstrated improved assay sensitivity, lower raw material usage, less waste and reduced workflow-related costs.

The global CLIA market is estimated at approximately US\$13 billion (2024) and is forecast to grow at approximately 6% CAGR. Successful entry would materially expand the diagnostics markets the Company serves. Pilot CLIA market entry opportunities, in South Korea, Japan and India continue to be assessed.

2. NEW ANTEOBIND™ NXT CLIA KIT – LAUNCH AT ADLM 2026

The magnetic particle activation test results achieved over the past several months are underpinning the launch of a new AnteoBind™ NXT CLIA Kit at ADLM 2026 in California in late July. By pairing beads from selected magnetic bead manufacturers with AnteoBind™ NXT and providing optimised activation protocols, these new kits are intended to move AnteoTech further up the diagnostics value chain, shifting the Company from a supplier of enabling chemistries to a provider of higher-value, bundled, ready-to-use solutions, supporting its CLIA market entry strategy.

3. JAPAN MARKET ENTRY – COSMO BIO DISTRIBUTION AGREEMENT

On 28 May 2026, the Company appointed Tokyo Stock Exchange-listed Cosmo Bio Co., Ltd (TSE: 3386) as a distributor of AnteoBind™ and related products in Japan, effective immediately. Cosmo Bio works with more than 600 suppliers and operates a well-established domestic distribution model servicing universities, public research institutes and life sciences companies throughout Japan.

The appointment establishes a non-exclusive sales channel in one of the world's largest in vitro diagnostics markets, supports service of existing Japanese customers including Chugai Pharmaceutical and the Japanese Red Cross Society, and may support Japan as an initial pilot market for CLIA kits and ELISA products.

4. SERUM INSTITUTE OF INDIA – CONTINUED SUPPLY

The Company's relationship with the Serum Institute of India (SII) continued under the five-year take-or-pay supply agreement. The Company shipped \$134,138 of AnteoBind™ to SII in early July 2026. As the shipment was delivered post 30 June 2026, this will be recorded as FY2027 income.

5. EXPANDING USE CASE

During the quarter multiple use cases for AnteoBind in India entered the public domain. In India, AnteoBind™ is increasingly being recognised as a platform-enabling surface chemistry that can improve biomolecule immobilisation, reporter conjugation, assay reproducibility and functional stability across different diagnostic formats. AnteoBind™ plays the strongest role where controlled immobilisation is critical.

These opportunities include in a sepsis test based on a lateral flow assay platform and an electrochemical biosensor system, with the potential for use in a paper-based Loop-Mediated Isothermal Amplification (LAMP) device.

In addition to the platform development work underway with our collaborators through the MOBIUS network, these use cases open up distinct application markets for AnteoBind™. Further details on these use cases are expected to be made available over the coming quarter.

C. CORPORATE AND FINANCIALS

LISTED OPTIONS EXERCISE AND UNDERWRITING

On 29 May 2026, the Company entered an underwriting agreement with MST Financial Services Pty Ltd in respect of up to 214,285,714 unexercised listed ADOO options (exercise price A\$0.035, expiring at 5:00pm Brisbane time on 31 May 2026). The agreement provided funding certainty ahead of the options' expiry, where MST subscribed for, or procured subscription for, any options not exercised by holders before expiry. MST also arranged sub-underwriting with sophisticated and professional investors, none of whom were related parties of the Company, and was entitled to a fee of 6% of the underwritten amount.

All of the 286,628,688 listed ADOO options were exercised. New fully paid ordinary shares were issued and quoted on ASX in two tranches: 118,326,435 shares on 2 June 2026 and 168,302,253 shares on 5 June 2026, raising approximately **A\$10.0 million** before costs. This materially strengthened the Company's balance sheet, with the funds being used to accelerate commercialisation across both businesses.

VICE PRESIDENT INTERNATIONAL SALES – DEPARTURE AND SALES REALIGNMENT

Subsequent to the end of the quarter, in July 2026, Mr Fabian Beck, Vice President of International Sales, left the business. Following his departure, global sales activities were centralised and are now fully coordinated from the Company's Brisbane head office. The Company thanks Mr Beck for his contribution.

Increased investment in sales and marketing by the Company spans marketing assets, tools and gaining access to new sales channels and networks as well as sales team growth. Working with the Company's growing international distributor base, facilitators and partner networks across South Korea, Japan, India and the United States, the Brisbane-based sales and marketing team continues to focus on sales growth.

ARENA GRANT – MILESTONE TIMELINE EXTENDED

During the quarter, the milestone timeline under the Company's Australian Renewable Energy Agency (ARENA) grant was extended to 15 November 2026. The revised timeline provides the Company with additional flexibility as it works to secure strategic partnerships required to progress the milestones.

CHIEF FINANCIAL OFFICER AND COMPANY SECRETARY

Mr Scott Waddell, who commenced as Interim Chief Financial Officer and Company Secretary on 2 February 2026, was confirmed in the permanent role of Chief Financial Officer and Company Secretary subsequent to quarter end on 17 July 2026.

CASH AND EXPENDITURE

As at 30 June 2026, the Company had a cash balance of **A\$11.2 million** with no bank debt, materially higher than the A\$3.291 million held at 31 March 2026, reflecting the ~A\$10.0 million received from the exercise of listed ADOO options (before deducting underwriting and offer costs), partly offset by operating expenditure during the quarter.

During the Quarter, customer receipts totalled A\$17,000, with a further A\$134,138 received from SII post quarter end, resulting in net cash outflows from operating activities of A\$1.585 million. A detailed summary of cash flows is provided in the accompanying Appendix 4C Quarterly Cash Flow Report.

Business Expenses	A\$'000
Research and Development	130
Staff, Admin and Corporate	1,276
Other	241
Total (excluding Revenue)	1,647

Capital Expenses	A\$'000
Plant and Equipment	10
Intellectual Property	66

ASX LISTING RULE 4.7C DISCLOSURE

During the Quarter, A\$159,000 was paid to related parties, as reported in Item 6.1 of the ASX Appendix 4C (Quarterly Cash Flow Report), for directors' fees.

D. LOOKING FORWARD

The Company's overarching objectives for the September 2026 quarter and the balance of FY2027 are the conversion of its LS and ABT customer sample trials and evaluations into sales, continued pipeline growth and securing strategic partnerships and/or investment. Specifically, by business:

A. LIFE SCIENCES

Significant focus and effort has gone into preparation for the launch of the new AnteoBind™ NXT CLIA Kit at ADLM 2026 in California, USA. New marketing collateral has been developed across the Company's CLIA, ELISA plate, Luminex and Lateral flow offerings as well as around the latest developments by the Company and will shortly be released.

New customer sales conversion including in Japan through Cosmo Bio and in India, together with continued SII supply, targeted marketing and conference attendance, will remain a focus.

B. ADVANCED BATTERY TECHNOLOGIES

Following the BIC commercial-format validation of Ultranode™ 95 around suitability for use in drones, the ABT team has dispatched Roll-to-Roll produced Ultranode™ 95 samples to US-based drone battery manufacturers, including one already supplying into the Military, for in-house validation, progress discussions with Australian defence sector drone suppliers, and will continue to advance the two Ultranode™ 95 JDA negotiations towards execution.

For Anteo S™, the focus is to progress the Xerabrid collaboration and supply combined samples of high-performance separators to large separator manufacturers globally and progress Anteo S™ samples currently under evaluation to pilot-scale evaluations or sales in Asia and the United States. For Anteo C, the Company will support customer evaluations in South Korea (via Xerabrid and Kangshin) and India and work towards commercial supply agreements.

The Company will also continue to support Wyon's Ultranode™ 70 commercial form-factor cell evaluations and seek to secure commercial supply arrangements, working with Wyon and through the Company's growing networks in South Korea and the USA.

C. CORPORATE

Sales and Marketing activities will continue from the Brisbane head office following the realignment of the international sales function. The Research and Development Tax rebate documentation will be progressed and lodged as part of the FY2026 tax work. The Company's FY2026 Annual Report is scheduled for release in September 2026. Work on the Company's new Website will commence shortly and be completed as expediently as possible.

This announcement has been authorised for release by the Board of AnteoTech Ltd.

– ENDS –

Media and investor enquiries: on +61 7 3219 0085 or investors@anteotech.com

Company and Partnering enquiries: Merrill Gray, MD/CEO, on +61 7 3219 0085

For further information, please refer to our website **www.anteotech.com**

About AnteoTech – (ASX: ADO)

AnteoTech is a supplier of advanced chemical and material solutions to the battery materials and life sciences markets. We leverage our market leading binding chemical platform technology to develop and commercialise solutions for our global customer base. From our patented high silicon anode cross linker product Anteo X™ to our ceramic coated separator product Anteo S™ and our Collector foil primer coating performance additive Anteo C through to our next-generation high silicon anode formulations Ultranode™ 70, 95 and X our Advanced Battery Technology business is applying its world-leading engineering expertise to address the growing demand for high performance, low cost, sustainable chemicals and materials within the global Lithium ion Battery market. Our Life Sciences business supplies advanced activation materials to leading developers and manufacturers of vaccines and diagnostic tests, through our AnteoBind™ suite of products. Our products deliver more sensitive and reproducible results and on incorporation in 'point of care' and other immunoassay diagnostic tests such as Chemiluminescence immunoassays (CLIA) and Enzyme-Linked Immunosorbent Assay (ELISA) plates, AnteoBind™ NXT enables faster, more reliable and more accurate test results wherever they are needed.

AnteoTech – Social Media Policy

AnteoTech is committed to communicating with the investment community through all available channels. Whilst ASX remains the prime channel for market sensitive news, investors and other interested parties are encouraged to follow AnteoTech on LinkedIn. Subscribe to AnteoTech Latest News emails – visit our website at www.anteotech.com and subscribe to receive our email alert service.

Forward Looking Statements

This Announcement may contain forward-looking statements, including estimates, projections and other forward-looking information (Estimates and Projections). Forward-looking statements can generally be identified by the use of forward-looking words such as “expect”, “anticipate”, “likely”, “intend”, “should”, “could”, “may”, “predict”, “plan”, “propose”, “will”, “believe”, “forecast”, “estimate”, “target”, “outlook”, “guidance” and other similar expressions within the meaning of securities laws of applicable jurisdictions and include, but are not limited to, indications of, or guidance or outlook on, future earnings or financial position or performance of AnteoTech. The Estimates and Projections are based on information available to AnteoTech as at the date of the Announcement, are based upon management’s current expectations, estimates, projections, assumptions and beliefs in regard to future events in respect to AnteoTech’s business and the industry in which it operates which may in time prove to be false, inaccurate or incorrect. The Estimates and Projections are provided as a general guide and should not be relied upon as an indication or guarantee of future performance. The bases for these statements are subject to risks and uncertainties that might be out of control of AnteoTech and may cause actual results to differ from the Announcement. No representation, warranty, or guarantee, whether express or implied, is made or given by AnteoTech in relation to any Estimates and Projections, the accuracy, reliability, or reasonableness of the assumptions on which the Estimates and Projections are based, or the process of formulating any Estimates and Projections, including that any Estimates and Projections contained in this Announcement will be achieved. AnteoTech takes no responsibility to make changes to these statements to reflect change of events or circumstances after the release.

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity

AnteoTech Ltd

ABN

75 070 028 625

Quarter ended ("current quarter")

30 June 2026

Consolidated statement of cash flows	Current quarter \$A'000	Year to date (12 months) \$A'000
1. Cash flows from operating activities		
1.1 Receipts from customers	17	410
1.2 Payments for		
(a) research and development	(130)	(482)
(b) product manufacturing and operating costs	(3)	(11)
(c) advertising and marketing	(39)	(310)
(d) leased assets/occupancy	(172)	(794)
(e) staff costs	(943)	(3,873)
(f) administration and corporate costs	(333)	(1,463)
1.3 Dividends received (see note 3)		
1.4 Interest received	45	63
1.5 Interest and other costs of finance paid	(27)	(88)
1.6 Income taxes paid		
1.7 Government grants and tax incentives	0	2,589
1.8 Other (PPL wages)	0	10
1.9 Net cash from / (used in) operating activities	(1,585)	(3,949)
2. Cash flows from investing activities		
2.1 Payments to acquire or for:		
(a) entities		
(b) businesses		
(c) property, plant and equipment	(10)	(55)
(d) investments		
(e) intellectual property	(66)	(225)
(f) other non-current assets		

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (12 months) \$A'000
2.2	Proceeds from disposal of:		
	(a) entities		
	(b) businesses		
	(c) property, plant and equipment		
	(d) investments		
	(e) intellectual property		
	(f) other non-current assets		
2.3	Cash flows from loans to other entities		
2.4	Dividends received (see note 3)		
2.5	Other (provide details if material)		
2.6	Net cash from / (used in) investing activities	(76)	(280)

3.	Cash flows from financing activities		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)		3,808
3.2	Proceeds from issue of convertible debt securities		
3.3	Proceeds from exercise of options	10,032	10,032
3.4	Transaction costs related to issues of equity securities or convertible debt securities	(461)	(750)
3.5	Proceeds from borrowings		
3.6	Repayment of borrowings		
3.7	Transaction costs related to loans and borrowings		
3.8	Dividends paid		
3.9	Other (provide details if material)		
3.10	Net cash from / (used in) financing activities	9,571	13,090

4.	Net increase / (decrease) in cash and cash equivalents for the period		
4.1	Cash and cash equivalents at beginning of period	3,291	2,340
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(1,585)	(3,949)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(76)	(280)

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (12 months) \$A'000
4.4	Net cash from / (used in) financing activities (item 3.10 above)	9,571	13,090
4.5	Effect of movement in exchange rates on cash held	0	0
4.6	Cash and cash equivalents at end of period	11,201	11,201

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter \$A'000	Previous quarter \$A'000
5.1	Bank balances	2,701	2,291
5.2	Term deposits (3-mth + 6-mth term)	8,500	1,000
5.3	Bank overdrafts		
5.4	Other		
5.5	Cash and cash equivalents at end of quarter (should equal item 4.6 above)	11,201	3,291

6.	Payments to related parties of the entity and their associates	Current quarter \$A'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	159
6.2	Aggregate amount of payments to related parties and their associates included in item 2	0
<i>Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.</i>		

7.	Financing facilities <i>Note: the term "facility" includes all forms of financing arrangements available to the entity.</i> <i>Add notes as necessary for an understanding of the sources of finance available to the entity.</i>	Total facility amount at quarter end \$A'000	Amount drawn at quarter end \$A'000
7.1	Loan facilities		
7.2	Credit standby arrangements		
7.3	Other (please specify)		
7.4	Total financing facilities	0	0
7.5	Unused financing facilities available at quarter end		0
7.6	Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.		

8.	Estimated cash available for future operating activities	\$A'000
8.1	Net cash from / (used in) operating activities (item 1.9)	(1,585)
8.2	Cash and cash equivalents at quarter end (item 4.6)	11,201
8.3	Unused finance facilities available at quarter end (item 7.5)	0
8.4	Total available funding (item 8.2 + item 8.3)	11,201
8.5	Estimated quarters of funding available (item 8.4 divided by item 8.1)	7.1
<i>Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.</i>		
8.6	If item 8.5 is less than 2 quarters, please provide answers to the following questions:	
8.6.1	Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?	
	Answer: N/A	
8.6.2	Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?	
	Answer: N/A	
8.6.3	Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?	
	Answer: N/A	
<i>Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.</i>		

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Authorised by the board
Scott Waddell
Company Secretary
20 July 2026

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee – eg Audit and Risk Committee]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.